Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX-410 and Pembrolizumab in Metastatic Triple Negative Breast Cancer
NCT03362060Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pvx-410 in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Primary endpoint: Immune Response at 3 years. Started Dec 2017; status: active, not recruiting.
02
Drugs
pvx-410
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03362060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362060.